Loading

Journal of Pharmacology and Clinical Toxicology

Esketamine Effects on Buprenorphine Treatment in a Comorbid Case of Opioid Addiction with Depression, Obsessive-Compulsive Disorder and Chronic Pain

Short Communication | Open Access
Article DOI :

  • 1. IU Addiction Psychiatry Program, Indiana University School of Medicine, USA
  • 2. Department of Psychiatry, Lab for Translational Neuroscience of Dual Diagnosis & Development, USA
+ Show More - Show Less
Corresponding Authors
Andrew Chambers R, Associate Professor of Psychiatry, Director, IU Addiction Psychiatry Training Program, Director, Lab for Translational Neuroscience of Dual Diagnosis & Development, IU Neuroscience Center, 320 W. 15th Street, Suite 314 D, Indianapolis, IN, 46202, USA, Tel: (317) 278-1716
ABBREVIATIONS

NMDA: N-methyl-D-aspartate: OCD: Obsessive Compulsive Disorder; MDD: Major Depressive Disorder; OUD: Opioid Use Disorder; FDA: Food and Drug Administration; REMS: Risk Evaluation and Mitigation Strategy.

INTRODUCTION

Ketamine, an N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, was first reported as producing rapid and sustained efficacy against major depressive disorder (MDD) over 20 years ago [1]. This finding has been thoroughly and rigorously replicated, representing one of the most significant breakthroughs in terms of novelty of mechanism, and robustness of efficacy in psychiatric pharmacology over these two decades [2]. Unfortunately, high risk misapplication of this treatment conducted outside of psychiatric expertise, direct medical supervision, or appropriate scientific observation, especially involving custom preparations of racemic ketamine, has been a growing concern that is now reaching attention in major news media [3]. Still, given the novel mechanism of action of this drug in targeting glutamate neurotransmission and neuroplasticity in brain circuits that are positioned at the nexus of addictions and mental disorder pathologies [4], it is important to fully explore the therapeutic potential of this drug, and others like it carefully, with a solid observational approach and clinical standards.

Here, we report a case experience in the use of esketamine, the intranasally-delivered enantiomer of ketamine that is the FDA-approved version (for chronic depression). Esketamine has been developed from research using the racemic form of ketamine (typically delivered orally, or intravenously that is not FDA-approved for depression). Notably, comparison studies between racemic ketamine and FDA-regulated esketamine have not identified major differences in efficacy (5 2538). In this case, we treated a patient with longstanding treatment refractory depression, who was also suffering with several other neuropsychiatric comorbidities including obsessive-compulsive disorder (OCD), chronic pain syndrome, opioid addiction (i.e. opioid use disorder (OUD)), and nicotine addiction (tobacco use disorder). As such, this patient represented a fairly typical case of severe, treatment refractory depression, that is often complicated by other psychiatric comorbidities and addiction. However, cases like this, which could warrant esketamine treatment, would provide a substantial challenge to most psychiatric or addiction treatment programs in the U.S. which typically do not provide integrated addiction and mental health care [5,6]. In this case, the patient with complex, ‘dual diagnosis’, comorbidities was treated with esketamine in a fully integrated addiction psychiatry clinic that provides a full spectrum of mental illness, addictions, and comorbidity care provided by board certified addiction psychiatrists and fellows [7]. To our knowledge, there are no prior reports of esketamine’s efficacy in a patient with OUD, depression, and other neuropsychiatric comorbidities while being treated with buprenorphine/naloxone.

MATERIALS AND METHODS

A 37-year-old, single, white male, living on disability income for psychiatric illness, had been treated successfully for his OUD over 2 years in our university-affiliated addiction psychiatry clinic, with buprenorphine/naloxone (a standard partial opioid agonist medication for the maintenance treatment of opioid addiction) at 16/4 mg daily. His treatment compliance and freedom from opioid relapses, was confirmed as steady and excellent by regular random drug testing and serial evaluations by the addiction psychiatrists. However, his depression, beginning in his teens with a suicide attempt at age 16, had been largely treatment-refractory and complicated by OCD that could encompass hours of rituals, cleaning and counting every day. As with most patients with opioid addiction, especially those with co-occurring mental illness, his opioid use disorder began iatrogenically (i.e., by medical over-prescribing) [8,9], in his teens and grew steadily during his 20’s via medically obtained prescriptions for back pain.

Given the steady severity of his major depressive disorder that had been refractory to prior standard medication trials, our team and the patient elected to proceed with a treatment course of intranasal esketamine (Brand name Spravato), with registration in the FDA-required Risk Evaluation and Mitigation Strategy (REMS) program. In this case, as an addiction psychiatry program, we were able to rigorously observe for and mitigate the risk of giving a controlled, psychoactive, and potentially addictive substance for a mental illness (esketamine), to a patient who was also suffering with 2 other comorbid addictions (to opioid and nicotine). Thus, the patient was only given the intranasal esketamine treatments under direct medical supervision in the clinic as per FDA-guidelines, while engaging in comprehensive addiction psychiatry services and monitoring.

Over an 8-month period, we delivered 17 doses of intranasal esketamine (56 mg) while the patient was continued on his baseline psychiatric medications, which were implemented to target his MDD and OCD (fluoxetine 60 mg and risperidone 3 mg daily). His treatment plan generally followed a pattern of receiving 2 treatments a week (separated by 2 days) for about 4 weeks, followed by one treatment a week for 4 weeks, then once monthly treatment for 5 months. A given treatment session would include the delivery of 14 mg of esketamine insufflated up each nostril (for total of 28 mg) in a first dosing round, followed by a second round 5 minutes later (another 28 mg) for total dosing of 56 mg. Vital signs were checked at baseline and at 40 and 120 minutes after treatment to monitor for blood pressure elevations that can occur with esketamine. The patient was required to stay in his treatment room for 2 hours after dosing and could read or use devices to listen to music or watch videos during that time. As with many patients receiving esketamine treatment, this patient did typically experience a state of mild pleasant euphoria acutely after treatment that was not cognitively impairing and resolving in about an hour to 90 minutes. This was followed by some degree of relief of depressive feelings that sustained for several days. Over the 17-session treatment course we employed commonly used rating scales for measuring symptom levels of MDD, OCD, and pain, always done 30 minutes prior to esketamine dosing, to observe for long-term trends that the treatment may be generating that could not have been produced by acute intoxication.

Consent was provided by the patient to have his case documented in the medical literature, reported without his identifying information.

RESULTS AND DISCUSSION

Remarkably, after the 4th esketamine session, the patient unexpectedly and without direction from the treatment team self-tapered his buprenorphine/naloxone from 16/4 to 8/2 mg daily over about a week, without experiencing opioid withdrawal, cravings, or worsening of pain (Table 1). While his MDD ratings remained fairly consistent with a transient improvement in the middle of his treatment course, his OCD severity decreased substantially in a more sustained pattern. After the 17 esketamine sessions, his buprenorphine/naloxone dosing never rebounded upward past the 8/2 mg daily dosing he established during the treatment, for the subsequent 2 years to present.

Table 1: Esketamine treatments per month with corresponding outcome scale values.

Month

#ESK

Treatments

PHQ-9

OCI-R

Pain Intensity

SBX Dose, mg

August

3

23

69

9

16

September

6

25

63

8

16 to 8

October

3

22

66

8

8

November

1

NA

NA

NA

8

December

1

16

59

8

8

January

1

NA

NA

NA

8

February

1

21

59

9

8

March

1

22

56

8

8

Abbreviations: Column results for depression, OCD and Pain intensity are averaged for each month due to limited variation. #ESK Treatments (number of sessions delivering 56 mg intranasal); PHQ-9 (Patient Health Questionnaire-9, depression scale), OCI-R (Obsessive Compulsive Inventory-Revised), pain intensity (subjective score, 0 (none) to 10(max) ); SBX dose (daily dose of Buprenorphine-naloxone, 4/1 mg ratio); NA = Not Assessed, patient received treatment on date senior author not present.

Ketamine has previously shown efficacy in reducing total opioid burden in chronic pain patients and in post-surgical opioid requirements when given intraoperatively [10]. This case builds upon this literature by documenting for the first time, a spontaneous 50% reduction in buprenorphine/naloxone dosing in a patient with opioid addiction. Although his MDD did not improve in a sustained way, his OCD did, also consistent with recent observations [11]. The intersection of MDD and OCD is a common [12], and likely reflects shared neuropathological substrates involving prefrontal cortical and striatal circuits that are “stuck” or overactive in representing perseverative thought content underpinning ruminative thinking and obsessions [13]. The intersection of chronic pain and depression is also very common, likely based on similar overlapping neuropathological substrates [14]. In this patients’ case it is interesting that his OCD responded better to esketamine in a more sustained way than his core MDD symptoms, although it is not unusual for complex psychiatric syndromes and their comorbidities to have specific components that improve differentially to treatments over time.

CONCLUSION

The glutamate neurotransmitter system is fundamental to information processing and neuroplastic change in the brain. This system is a shared substrate in the integrated pathogenesis of many forms of mental illness and addictions that show convergent circuity and bidirectional causal interactions, particularly within frontal-cortical, ventral-striatal circuits, that mediate decision-making, affective awareness and motivational control [15,16]. Thus, medications that can produce enduring changes in information professing and plasticity mediated by glutamate neurotransmission within these circuits, like esketamine, may have multi-faceted potential to improve a range of mental illness and addiction disease trajectories. This report suggests the therapeutic value of esketamine, and other glutamatergic agents for complex comorbidities of mental illness and addictions, to enhance phasic transitions through recovery trajectories [17]. Further study of ketamine and other glutamate modulators, done while adhering to FDA guidelines, executed buy well-trained clinicians with attention to ethical standards, and a commitment to scientific reporting, should be conducted over an array of indications and patients with various forms of dual diagnosis comorbidities. Addition psychiatry treatment programs may be ideally suited to this given their expertise in comorbid patients, and rigorous balanced attention to monitoring for both mental illness and addiction-disease outcomes.

ACKNOWLEDGMENTS

NB is a beneficiary of an HRSA-Addiction Medicine Training grant (T25HP37617) on which RAC is PI. RAC is also supported by NIDA UG3 DA050923 (as PI).

We thank our patient for allowing his clinical story to be shown in the literature.

REFERENCES
  1. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000; 47: 351-354.
  2. Iadarola ND, Niciu MJ, Richards EM, Vande Voort JL, Ballard ED, Lundin NB, et al. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis. 2015; 6: 97-114.
  3. Hamby C. Ketamine Treatment, and Abuse, Made Easier by Telemedicine. New York Times. 2023 Feb. 20, 2023; Sect. A.
  4. Chambers RA. Impulsivity, dual diagnosis, and the structure of motivated behavior in addiction. Behavioral and Brain Sciences. 2008; 31: 443-444.
  5. Correia-Melo FS, Leal GC, Vieira F, Jesus-Nunes AP, Mello RP, Magnavita G, et al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. J Affect Disord. 2020; 264: 527-534.
  6. Canady V. SAMHSA NSDUH report findes increases in mental health, co-occurring disorders. Mental Health Weekly. 2020; 30: 1-3.
  7. Chambers RA. The 2 x 4 model: a neuroscience-based blueprint for the modern integrated addiction and mental health treatment system. First edition. ed. New York, NY: Routledge; 2018.
  8. Wright ER, Kooreman HE, Greene MS, Chambers RA, Banerjee A, Wilson J. The iatrogenic epidemic of prescription drug abuse: countylevel determinants of opioid availability and abuse. Drug Alcohol Depend. 2014; 138: 209-215.
  9. Davis MA, Lin LA, Liu H, Sites BD. Prescription Opioid Use among Adults with Mental Health Disorders in the United States. J Am Board Fam Med. 2017; 30: 407-417.
  10. Culp C, Kim HK, Abdi S. Ketamine Use for Cancer and Chronic Pain Management. Front Pharmacol. 2020; 11: 599721.
  11. Bandeira ID, Lins-Silva DH, Cavenaghi VB, Dorea-Bandeira I, Faria-Guimaraes D, Barouh JL, et al. Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review. Harv Rev Psychiatry. 2022; 30: 135-145.
  12. Overbeek T, Schruers K, Vermetten E, Griez E. Comorbidity of obsessive-compulsive disorder and depression: prevalence, symptom severity, and treatment effect. J Clin Psychiatry. 2002; 63: 1106-1112.
  13. Macpherson T, Hikida T. Role of basal ganglia neurocircuitry in the pathology of psychiatric disorders. Psychiatry Clin Neurosci. 2019; 73: 289-301.
  14. 14. Feingold D, Brill S, Goor-Aryeh I, Delayahu Y, Lev-Ran S. The association between severity of depression and prescription opioid misuse among chronic pain patients with and without anxiety: A cross-sectional study. J Affect Disord. 2018; 235: 293-302.
  15. Chambers RA, Bickel WK, Potenza MN. A scale-free systems theroy of motivation and addiction. Neurosciene and Biobehavioral Reviews. 2007; 31: 1017-1045.
  16. Chambers RA, Sentir AM, Conroy SK, Truitt WA, Shekhar A. Corticalstriatal integration of cocaine history and prefrontal dysfunction in animal modeling of dual diagnosis. Biol Psychiatry. 2010; 67: 788- 792.
  17. Chambers RA, Toombs C. Deep Network Pharmacology: Targeting Glutamate Systems as Integrative Treatments for Jump-Starting Neural Networks and Recovery Trajectories. J Psychiatr Brain Sci. 2021; 6.
Received : 04 Apr 2023
Accepted : 29 Mar 2023
Published : 31 Mar 2023
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X